Literature DB >> 9188591

Role for highly regulated rep gene expression in adeno-associated virus vector production.

J Li1, R J Samulski, X Xiao.   

Abstract

Recent success achieving long-term in vivo gene transfer without a significant immune response by using adeno-associated virus (AAV) vectors (X. Xiao, J. Li, and R. J. Samulski, J. Virol. 70:8098-8108, 1996) has encouraged further development of this vector for human gene therapy. Currently, studies focus on the generation of high-titer vectors by using the two-plasmid helper-vector system in adenovirus (Ad)-infected cells. To examine the effects of the AAV replication (rep) genes on recombinant AAV (rAAV) vector production, we have constructed a series of AAV helper plasmids that contain strong heterologous promoters in place of the endogenous p5 promoter. Although high-level rep gene expression was achieved, rAAV DNA failed to replicate in the absence of Ad infection. Moreover, unregulated overexpression of Rep78/68 led to substantially lower rAAV yields in the presence of Ad (10(4-5) versus 10(7-8)). In contrast, under similar conditions, reduced Rep78/68 expression resulted in much higher rAAV yields (10(9)). Molecular characterization showed that overexpression of the rep gene decreased rAAV DNA replication and severely inhibited capsid (cap) gene expression. Interestingly, a reduced rep level enhanced cap gene expression and supported normal rAAV DNA replication. These studies suggest a critical role for regulated rep gene expression in rAAV production and have facilitated the development of a new AAV helper plasmid that increases vector production eightfold over currently used constructs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9188591      PMCID: PMC191759          DOI: 10.1128/JVI.71.7.5236-5243.1997

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

Review 1.  Adenovirus and adeno-associated virus as vectors for gene therapy.

Authors:  K I Berns; C Giraud
Journal:  Ann N Y Acad Sci       Date:  1995-11-27       Impact factor: 5.691

2.  Inhibition of cellular and SV40 DNA replication by the adeno-associated virus Rep proteins.

Authors:  Q Yang; F Chen; J Ross; J P Trempe
Journal:  Virology       Date:  1995-02-20       Impact factor: 3.616

3.  An improved system for packaging recombinant adeno-associated virus vectors capable of in vivo transduction.

Authors:  T R Flotte; X Barraza-Ortiz; R Solow; S A Afione; B J Carter; W B Guggino
Journal:  Gene Ther       Date:  1995-01       Impact factor: 5.250

4.  Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors.

Authors:  F K Ferrari; T Samulski; T Shenk; R J Samulski
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

5.  Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis.

Authors:  K J Fisher; G P Gao; M D Weitzman; R DeMatteo; J F Burda; J M Wilson
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

6.  Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration.

Authors:  T R Flotte; S A Afione; P L Zeitlin
Journal:  Am J Respir Cell Mol Biol       Date:  1994-11       Impact factor: 6.914

7.  Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain.

Authors:  M G Kaplitt; P Leone; R J Samulski; X Xiao; D W Pfaff; K L O'Malley; M J During
Journal:  Nat Genet       Date:  1994-10       Impact factor: 38.330

Review 8.  Adeno-associated virus vectors for gene therapy.

Authors:  T R Flotte; B J Carter
Journal:  Gene Ther       Date:  1995-08       Impact factor: 5.250

9.  Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor.

Authors:  T Dobner; N Horikoshi; S Rubenwolf; T Shenk
Journal:  Science       Date:  1996-06-07       Impact factor: 47.728

10.  Mutational analysis of adeno-associated virus Rep protein-mediated inhibition of heterologous and homologous promoters.

Authors:  M Hörer; S Weger; K Butz; F Hoppe-Seyler; C Geisen; J A Kleinschmidt
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

View more
  62 in total

1.  Kinetics of recombinant adeno-associated virus-mediated gene transfer.

Authors:  A K Malik; P E Monahan; D L Allen; B G Chen; R J Samulski; K Kurachi
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  High-titer, wild-type free recombinant adeno-associated virus vector production using intron-containing helper plasmids.

Authors:  L Cao; Y Liu; M J During; W Xiao
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Adeno-associated virus RNAs appear in a temporal order and their splicing is stimulated during coinfection with adenovirus.

Authors:  M B Mouw; D J Pintel
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols.

Authors:  T Yoshida; K Okuda; K Q Xin; K Tadokoro; J Fukushima; S Toda; E Hagiwara; K Hamajima; T Koshino; T Saito
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

5.  Efficient replication of adeno-associated virus type 2 vectors: a cis-acting element outside of the terminal repeats and a minimal size.

Authors:  G E Tullis; T Shenk
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  Cloning of an avian adeno-associated virus (AAAV) and generation of recombinant AAAV particles.

Authors:  Ioannis Bossis; John A Chiorini
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

7.  Transient demyelination increases the efficiency of retrograde AAV transduction.

Authors:  Edmund R Hollis; Pouya Jamshidi; Ariana O Lorenzana; Jae K Lee; Steven J Gray; Richard J Samulski; Binhai Zheng; Mark H Tuszynski
Journal:  Mol Ther       Date:  2010-05-25       Impact factor: 11.454

Review 8.  Gene therapy for Fabry disease.

Authors:  C Siatskas; J A Medin
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

9.  Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity.

Authors:  Joseph E Rabinowitz; Fabienne Rolling; Chengwen Li; Hervè Conrath; Weidong Xiao; Xiao Xiao; R Jude Samulski
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

10.  Improved splicing of adeno-associated viral (AAV) capsid protein-supplying pre-mRNAs leads to increased recombinant AAV vector production.

Authors:  K David Farris; David J Pintel
Journal:  Hum Gene Ther       Date:  2008-12       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.